Two Sisters with Colchicine-Resistant form of Familial Mediterranean Fever on the Canakinumab Therapy: Clinical Case

Background. Colchicine-resistant cases of familial Mediterranean fever (FMF) are associated with high risk of kidney amyloidosis and severe episodes of the disease with pyretic fever, arthritis, pleurisies, pericarditis. It is difficult to achieve disease control in colchicine-resistant patients and it is required to use genetically engineered biologic drugs.

Clinical Case Description. The observation of the family with severe course of FFL is presented. The successful use of canakinumab (monoclonal antibody to interleukin-1) in sisters with colchicine-resistant form of disease is described. Fever, articular and abdominal syndromes were completely reversed after 4 weeks of treatment as well as normalisation of laboratory tests was noted. Laboratory indexes of disease activity (erythrocyte sedimentation rate and C-reactive protein level) have stayed in reference ranges after 32 weeks of therapy, no new episodes of the disease were recorded. There were no adverse effect on the canakinumab therapy during the observation period (32 weeks).

Conclusion. The high canakinumab efficacy in patients with severe colchicine-resistant forms of FMF is shown.

1. Chae JJ, Wood G, Richard K, et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kB through its N-terminal fragment. Blood. 2008;112:1794-1803. doi: 10.1182/blood-2008-01-134932.

2. Lobanova OS, Voloshinova EV. Nekotoryye osobennosti techeniya semeynoy sredizemnomorskoy likhoradki, oslozhnennoy razvitiyem AA-amiloidoza. Archive of internal medicine. 2015;(1):7-11. (In Russ).

3. Ben-Chetrit E, Touitou I. Familial Mediterranean fever in the World. Arthritis Rheum. 2009;61(10):1447-1453. doi: 10.1002/art.24458.

4. Zadeh N, Getzug T, Grody WW. Diagnosis and management of familial Mediterranean fever: integrating medical genetics in a dedicated interdisciplinary clinic. Genet Med. 2011;13(3):263-269. doi: 10.1097/GIM.0b013e31820e27b1.

5. Ozen S, Hoffman HM, Frenkel J, Kastner D. Familial Mediterranean Fever (FMF) and beyond: a new horizon. Fourth International Congress on the Systemic Autoinflammatory Diseases held in Bethesda, USA, 6-10 November 2005. Ann Rheum Dis. 2006;65(7):961-964. doi: 10.1136/ard.2006.052688.

6. Kuijk LM, Hoffman HL, Neven B, Frenkel J. Episodic Autoinflammatory Disorders in Children. In: Cimas R, Lehman T (eds). Handbook of Systemic Autoimmune Disease. Vol. 6. Pediatrcs in Systemic Autoimmune Disease. Elselvier; 2008. Рр. 119-135.

7. Ozen S, Frenkel J, Ruperto N, et al. The Eurofever project: towards better care for autoinflammatory disease. Eur J Pediatr. 2011; 170(4):445-452. doi: 10.1007/s00431-0111411-z.

8. Janeway TC, Mosenthal H. Unusual paroxysmal syndrome, probably allied to recurrent vomiting, with a study of nitrogen metabolism. Trans Assoc Am Physicians. 1908;23:504-518.

9. Reimann HA. Periodic disease; a probable syndrome including periodic fever, benign paroxysmal peritonitis, cyclic neutropenia and intermittent arthralgia. J Am Med Assoc. 1948;136(4):239-244. doi: 10.1001/jama.1948.02890210023004.

10. Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet. 2001;9(7):473-483. doi: 10.1038/sj.ejhg.5200658.

11. Centola M, Wood G, Frucht DM, et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood. 2000;95(10):3223-3231. doi: 10.1182/blood.v95.10.3223.010k26_3223_3231.

12. Diaz A, Hu C, Kastner DL, et al. Lipopolysaccharide-induced expression of multiple alternatively spliced MEFV transcripts in human synovial fibroblasts: a prominent splice isoform lacks the C-terminal domain that is highly mutated in familial Mediterranean fever. Arthritis Rheum. 2004;50(11):3679-3689. doi: 10.1002/art.20600.

13. Korkmaz C, Ozdogan H, Kasapcopur O, Yazici H. Acute phase response in familial Mediterranean fever. Ann Rheum Dis. 2002; 61(1):79-81. doi: 10.1136/ard.61.1.79.

14. The International FMF Consortium. Ancient missense mutation in a new member of the RoReT gene family are likely to cause Familial Mediterranean Fever. Cell. 1997;90(4):797-807. doi: 10.1016/s0092-8674(00)80539-5.

15. Fedorov ES, Salugina SO, Kuzmina N.N. Familial Mediterranean fever (a periodic disease): the present-day view of the problem. Sovremennaya revmatologiya. 2013;7(1): 24-30. (In Russ). doi: 10.14412/1996-7012-2013-2363.

16. Park YH, Wood G, Kastner D, Chae JJ. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol. 2016;17(8):914-921. doi: 10.1038/ni.3457.

17. Omenetti A, Carta S, Delfino L, et al. Increased NLRP3-dependent interleukin 1p secretion in patients with familial Mediterranean fever: correlation with MEFV genotype. Ann Rheum Dis. 2014;73(2): 462-469. doi: 10.1136/annrheumdis-2012202774.

18. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Meditarranean fever. Ann Rheum Dis. 2016;75(4):644-651. doi: 10.1136/annrheumdis-2015-208690.

19. Simon A, et al. Familial autoinflammatory syndromes. In: Fires-tein G, Budd R, Gabriel SE, et al, eds. Kelley's Textbook of Rheumatology. 8th ed. Philadelphia, PA: Saunders; 2008. Рр. 1863-1882.

20. Ben-Zvi I, Herskovizh C, Kukuy O, et al. Familial Mediterranean fever without MEFV mutations: a case-control study. Orphanet J Rare Dis. 2015;10:34. doi: 10.1186/s13023-015-0252-7.

21. Shcherbakova MYu, Yaroshevskaya OYu, Gurevich OE, et al. Sluchay periodicheskoy bolezni s iskhodom v amiloidoz u mal'chika 15 let. Zhurnal imeni G.N. Speranskogo. Pediatria. 2006;(4):111-114. (In Russ).

22. French FMF Consorcium. A candidate gene for Familial Mediterranean Fever. J Nat Genet. 1997;17(1):25-31. doi: 10.1038/ng0997-25.

23. Berdeli A, Mukctarova G, Oz A, Musayev S. MEFV gene mutation distrubution in Azerbaijan population. Pediatr Rheumatol. 2015; 13(Suppl 1):127. doi: 10.1186/1546-0096-13-S1-P127.

24. Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Semin Arthritis Rheum. 2013;43(3):387-391. doi: 10.1016/j.semarthrit.2013.04.011.

25. Kostik MM, Zhogova OV, Lagunova NV, et al. Familial mediterranean fever: current approaches to diagnosis and treatment. Current Pediatrics. 2018;17(5):371-380. (In Russ). doi: 10.15690/vsp.v17i5.1953.

26. Ozturk MA, Kanbay M, Kasapoglu B, et al. Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S77-86.

27. Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or-intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157(8):533-541. doi: 10.7326/0003-4819-157-8-201210160-00003.

28. ClinicalTrials.gov. Study of efficacy and safety of Canakinumab in patients with hereditary periodic fevers. ClinicalTrials.gov Identifier: NCT02059291 [Internet]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02059291.

29. Gul A, Ozdogan H, Erer B, et al. Efficacy and safety of canakinu-mab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther. 2015;17:243. doi: 10.1186/s13075-015-0765-4.

30. Jarjour RA, Al-Berrawi S. Familial Mediterranean fever in Syrian children: phenotype-genotype correlation. Rheumatol Int. 2015; 35(4):629-634. doi: 10.1007/s00296-014-3116-x.

31. Celkan T, Celik M, Kasapcopur O, et al. The anemia of familial Mediterranean fever disease. Pediatr Hematol Onco. 2005;22(8): 657-665. doi: 10.1080/08880010500278681.

32. Barut K, Sahin S, Adrovic A, et al. Familial Mediterranean fever in childhood: a single-center experience. Rheumatol Int. 2018; 38(1):67-74. doi: 10.1007/s00296-017-3796-0.

33. Yalcinkaya F, Ozen S, Ozcakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009;48(4):395-398. doi: 10.1093/rheu-matology/ken509.

34. Rawashdeh MO, Majeed HA. Familial Mediterranean fever in Arab children: the high prevalence and gene frequency. Eur J Pediatr. 1996;155(7):540-544. doi: 10.1007/bf01957901.

35. Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84(1):1-11. doi: 10.1097/01.md.0000152370.84628.0c.